human breast cancer cell lines mda mb her2  (ATCC)

Journal: Frontiers in Pharmacology

Article Title: Low-dose statins restore innate immune response in breast cancer cells via suppression of mutant p53

doi: 10.3389/fphar.2025.1492305

Figure Lengend Snippet: Mutant p53 inhibits innate immune signaling in breast cancer. Survival analysis of TP53-Mutant and TP53-NonMutant groups in breast cancer patients (A) . Expression of STING in breast cancer with TP53-Mutant group versus TP53-NonMutant group, *p < 0.05 (B) . Immunoprecipitation of mutant P53 in whole-cell lysates from MDA-MB-231 (p53 R280K ) and Sk-Br-3 (p53 R175H ) cells. Immunoblot analysis of lysates and immunoprecipitates (C) . Western blot analysis of cGAS-STING pathway proteins in the human breast cancer cell lines MDA-MB-231 (P53 R280K ) and Sk-Br-3 (P53 R175H ) following shp53 (D) . Western blot analysis of cGAS-STING pathway proteins in 4T1 cells transfected with p53R280K, using 4T1 (p53 null ) cells transfected with shCOO2 as the control (E) .

Article Snippet: Human breast cancer cell lines MDA-MB-231 (p53 R280K ), Sk-Br-3 (p53 R175H ), BT-549 (p53 R249S ), MDA-MB-468 (p53 R273H ), and MCF7 (wild-type p53) and mouse breast cancer cell line 4T1 were procured from ATCC and cultured accordingly in DMEM or RPMI-1640 with 10% FBS and 1% antibiotics.

Techniques: Mutagenesis, Expressing, Immunoprecipitation, Western Blot, Transfection, Control

Journal: Frontiers in Pharmacology

Article Title: Low-dose statins restore innate immune response in breast cancer cells via suppression of mutant p53

doi: 10.3389/fphar.2025.1492305

Figure Lengend Snippet: Prolonged low-dose statins reduce mutant p53 and activate innate immunity in breast cancer cells. Western blot analysis of MDA-MB-231 (p53 R280K ) and 4T1 (p53 R280K ) cells treated with low-dose statins collected at 0, 24, 48, 72, 96, and 120 h (A) . MDA-MB-231 (p53 R280K ) cells were treated with indicated concentrations of fluvastatin (0, 0.12, 0.25, 0.5 μM) and lovastatin (0, 4 μM) for 120 h, respectively, and cell samples were collected for western blot experiments (B) . Empty vector plasmid shC002 transfected 4T1 (p53 null ) cells and mutant p53-transfected 4T1 (p53 R280K ) cells were treated with indicated concentrations of fluvastatin (0, 0.5 μM) and lovastatin (0, 0.5 μM) for 120 h, respectively, and cell samples were collected for western blot experiments (C, D) .

Article Snippet: Human breast cancer cell lines MDA-MB-231 (p53 R280K ), Sk-Br-3 (p53 R175H ), BT-549 (p53 R249S ), MDA-MB-468 (p53 R273H ), and MCF7 (wild-type p53) and mouse breast cancer cell line 4T1 were procured from ATCC and cultured accordingly in DMEM or RPMI-1640 with 10% FBS and 1% antibiotics.

Techniques: Mutagenesis, Western Blot, Plasmid Preparation, Transfection

Journal: Frontiers in Pharmacology

Article Title: Low-dose statins restore innate immune response in breast cancer cells via suppression of mutant p53

doi: 10.3389/fphar.2025.1492305

Figure Lengend Snippet: Low-dose statins boost IRF3 nuclear translocation and ISGs in mutant p53 breast cancer. MDA-MB-231 (p53R280K) cells were treated with indicated concentrations of fluvastatin (0, 0.12, 0.25, 0.5 μM) for 120 h, followed by nuclear-cytoplasmic fractionation experiments and western blot analysis to assess IRF3 protein expression (A) . 4T1 (p53 null ) cells transfected with empty vector plasmid shC002 and mutant p53-transfected 4T1 (p53 R280K ) cells were treated with indicated concentrations of fluvastatin (0, 0.5 μM) for 120 h, then subjected to nuclear-cytoplasmic fractionation experiments and western blot analysis to evaluate IRF3 protein expression (B) . MDA-MB-231 (p53 R280K ) cells were treated with 0.5 μM fluvastatin and 0.5 μM lovastatin for 120 h, respectively, followed by cell sample collection for RT-PCR detection of CXCL10 and ISG15 mRNA. N = 3, *p < 0.05, **p < 0.01, ***p < 0.001 (C) . Mutant p53-transfected 4T1 (p53 R280K ) cells were treated with 0.5 μM fluvastatin and 0.5 μM lovastatin for 120 h, respectively, and cell samples were collected for RT-PCR analysis of IFNB1 mRNA. N = 3, **p < 0.01 (D) .

Article Snippet: Human breast cancer cell lines MDA-MB-231 (p53 R280K ), Sk-Br-3 (p53 R175H ), BT-549 (p53 R249S ), MDA-MB-468 (p53 R273H ), and MCF7 (wild-type p53) and mouse breast cancer cell line 4T1 were procured from ATCC and cultured accordingly in DMEM or RPMI-1640 with 10% FBS and 1% antibiotics.

Techniques: Translocation Assay, Mutagenesis, Fractionation, Western Blot, Expressing, Transfection, Plasmid Preparation, Reverse Transcription Polymerase Chain Reaction

Journal: Frontiers in Pharmacology

Article Title: Low-dose statins restore innate immune response in breast cancer cells via suppression of mutant p53

doi: 10.3389/fphar.2025.1492305

Figure Lengend Snippet: Statin inhibition of proliferation in mutant p53 breast tumors in an intact host immune system. Monitoring of body weight during a 3-week treatment period of 4T1 (p53 R280K ) lovastatin and control groups. 4T1 (p53 R280K ) treated group n = 9, 4T1 (p53 R280K ) control group n = 10. *p < 0.05 (A) . Monitoring of mammary tumor growth in the two groups mentioned in (A) over the 3-week treatment period. *p < 0.05 (B) . Photographic documentation of tumors from dissected BALB/c mice in the two groups mentioned in (A) following treatment termination (C) . Statistical analysis of tumor volumes from (C) , *p < 0.05 (D) . Statistical analysis of tumor weights from (C) , *p < 0.05 (E) .

Article Snippet: Human breast cancer cell lines MDA-MB-231 (p53 R280K ), Sk-Br-3 (p53 R175H ), BT-549 (p53 R249S ), MDA-MB-468 (p53 R273H ), and MCF7 (wild-type p53) and mouse breast cancer cell line 4T1 were procured from ATCC and cultured accordingly in DMEM or RPMI-1640 with 10% FBS and 1% antibiotics.

Techniques: Inhibition, Mutagenesis, Control

Journal: Frontiers in Pharmacology

Article Title: Low-dose statins restore innate immune response in breast cancer cells via suppression of mutant p53

doi: 10.3389/fphar.2025.1492305

Figure Lengend Snippet: Statin activation of innate immune suppression in mutant p53 breast cancer tumor growth. 4T1 (p53 R280K ) BALB/c mice were euthanized on day 23, tumors were excised, sectioned, and subjected to immunoblot analysis of tumor tissue (A) . Representative immunohistochemistry images of p53, CD3 + CD8 + T lymphocyte infiltration. Magnification is 200* (B) .

Article Snippet: Human breast cancer cell lines MDA-MB-231 (p53 R280K ), Sk-Br-3 (p53 R175H ), BT-549 (p53 R249S ), MDA-MB-468 (p53 R273H ), and MCF7 (wild-type p53) and mouse breast cancer cell line 4T1 were procured from ATCC and cultured accordingly in DMEM or RPMI-1640 with 10% FBS and 1% antibiotics.

Techniques: Activation Assay, Mutagenesis, Western Blot, Immunohistochemistry